Biphenyl dimethyl dicarboxylate.
Hepasel (biphenyl dimethyl dicarboxylate) is dimethyl-4,4'-dimethoxy-5, 6,5'6'-dimethylenedioxy-biphenyl-2,2'-dicarboxylate (DDB). It is a synthetic analogue of schizandrin C which was isolated from Fructus Schizandrae chinensis, a traditional Chinese medicinal plant. The empirical formula is C20H16O10 and molecular weight of 418.96 available in white crystal.
Pharmacology: DDB was shown to protect against hepatic injury induced by chemical toxins eg, prednisolone, carbon tetrachloride, thioacetamide and D-galactosamine in mice and rabbits. DDB inhibits carbon tetrachloride-induced lipid peroxidation of liver microsomes and the covalent binding of carbon tetrachloride to microsomal lipids. In addition, DDB significantly increased the liver detoxicating ability and antagonized the mutagenicity of chemical carcinogens eg, aflatoxin B and benz(a)pyrene.
Toxicology: The toxicity of DBB is very low.
Carcinogenicity & Mutagenicity: No teratogenic or mutagenic effect was detected.
Clinical Effects: Rapid drop in SGPT. The elevated SGPT levels of 80-85% of the patients returned to normal after treatment.
Restoring normal ratio of serum albumin and globulin (A/G), and improving thymol fluctuation test (TFT).
Decreasing the elevated serum α-fetal protein (α-FP) and bilirubin at an effective rate of 80%.
Relieving symptoms eg, hepatic pain, fatigue, abdominal tension and anorexia.
Ameliorating liver pathological changes. Such improvements can be examined through the liver biopsies performed before and after treatment.
The SGPT-lowering effect of DBB in the patients was found to be much better than that of silymarin (Legalon) and glycyrrhizin (Stronger Neo Minophagen C).
No side effects of DDB have been observed.
Viral hepatitis, drug- or alcohol-induced hepatitis, fatty liver, hepato-cirrhosis, hepatic pain, fatigue and anorexia.
1-2 caps to be taken, 3 times daily.
Store in a cool, dry place. Protect from direct sunlight.
Shelf-Life: 3 years.
A05BA - Liver therapy ; Used in liver therapy.